Study summary

Targeted pills mostly held chordoma steady rather than shrinking it

Targeted pills review · Pooled single-arm studies · Published January 2025, Neurosurgical Review

What was tested

A pooled look at single-arm studies of tyrosine kinase inhibitors such as imatinib for advanced or metastatic chordoma.

What they found

• Median time before growth was 8.41 months and median survival about 36 months.
• Imatinib was linked to longer survival than other pills.
• Side effects were very common; 55% had serious ones.

What it means

Pills can slow chordoma, but better drugs are needed.